GO:0032691 negative regulation of interleukin-1 beta production: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032691 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-1 beta (IL-1β) production.
• IL-1β is a potent pro-inflammatory cytokine produced mainly by blood monocytes and macrophages, and its excessive production drives tissue injury in inflammatory and metabolic diseases.
• Negative regulation of IL-1β production can occur at multiple levels, including inhibition of inflammasome-dependent caspase-8 and Ripk3/Mlkl signaling by Ptpn6, and metabolic suppression via lactate-GPR81 signaling.
• Succinate accumulation can promote IL-1β production through HIF-1α, revealing that mitochondrial metabolites are key nodes in the regulation of IL-1β.
• Macrophage SUCLA2 couples glutaminolysis to AMPK signaling to manipulate obesity, linking IL-1β regulation to systemic metabolism.
• Tim-3 upregulation alleviates liver injury by regulating macrophage activation in NASH, providing a therapeutic handle on IL-1β-driven inflammation.
Description
Interleukin-1 beta (IL-1β) is a central mediator of innate immunity and inflammation, produced primarily by blood monocytes and macrophages in response to infection or tissue damage. Because uncontrolled IL-1β production contributes to chronic inflammatory and metabolic diseases, the cell has evolved multiple mechanisms to negatively regulate its production, collectively annotated as GO:0032691 negative regulation of interleukin-1 beta production. Understanding these mechanisms is essential for researchers seeking to modulate inflammation in conditions such as osteoarthritis, acne, nonalcoholic steatohepatitis (NASH), and obesity. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the genes, pathways, and experimental models relevant to GO:0032691.
negative regulation of interleukin-1 beta production At A Glance
| GO ID | GO:0032691 |
|---|---|
| GO term | negative regulation of interleukin-1 beta production |
| Ontology | biological_process |
| Synonym | inhibition of interleukin-1 beta production; negative regulation of IL-1 beta production; downregulation of interleukin-1 beta production |
| Major function | Suppression of IL-1β biosynthesis and secretion to limit inflammation |
| Key regulators | Ptpn6, Tim-3 (HAVCR2), GPR81 (HCAR1), SUCLA2, HIF-1α |
| Associated diseases | Osteoarthritis, acne, NASH, obesity, inflammatory tissue injury |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics, cytokine assays |
What Is GO:0032691?
GO:0032691 negative regulation of interleukin-1 beta production is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-1 beta production. This includes inhibition of IL-1β biosynthesis, secretion, or both, and encompasses molecular events such as suppression of inflammasome activation, modulation of cytokine gene transcription, and interference with vesicular trafficking of IL-1β.
Why Is negative regulation of interleukin-1 beta production Important in Cell Biology?
Negative regulation of IL-1β production is critical for preventing excessive inflammation and tissue damage. Dysregulation of this process is linked to a wide range of human diseases, including osteoarthritis, acne, NASH, and obesity. Understanding the molecular players that suppress IL-1β production can reveal new therapeutic targets for inflammatory and metabolic disorders.
• Prevents chronic inflammation by limiting IL-1β-driven tissue injury.
• Modulates innate immune responses in liver, pancreas, and adipose tissue.
• Influences the pathogenesis of osteoarthritis through pro-inflammatory cytokine networks.
• Contributes to acne pathogenesis via diet-metabolome-inflammation links.
• Regulates macrophage activation in NASH and other liver diseases.
• Involves metabolic checkpoints such as succinate-HIF-1α and lactate-GPR81 signaling.
• Provides targets for CRISPR-based functional genomics in inflammation research.
• Links mitochondrial metabolism (SUCLA2, glutaminolysis) to inflammatory cytokine control.
• Offers opportunities for therapeutic intervention in obesity and metabolic syndrome.
• Serves as a model process for studying negative regulation of cytokine production in general.
What Happens During negative regulation of interleukin-1 beta production?
Inhibition of Inflammasome-Dependent IL-1β Maturation
In simple terms: The cell blocks the molecular machine that cuts pro-IL-1β into its active form.
IL-1β is produced as an inactive precursor that requires cleavage by inflammasome-associated caspases. Negative regulation can occur through inhibition of caspase-8 and Ripk3/Mlkl-dependent inflammasome signaling. For example, the phosphatase Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation, thereby reducing IL-1β production. This represents a direct intracellular brake on IL-1β maturation.
Metabolic Suppression of IL-1β via Lactate-GPR81 Signaling
In simple terms: A metabolite produced during stress can tell immune cells to make less IL-1β.
Lactate, acting through the G-protein-coupled receptor GPR81 (HCAR1), suppresses innate immunity and reduces inflammasome-mediated inflammation in liver and pancreatic injury models. This pathway exemplifies how metabolic signals negatively regulate IL-1β production, linking cellular metabolism to cytokine control.
Regulation by Mitochondrial Metabolites and HIF-1α
In simple terms: Mitochondrial chemicals can either boost or dampen IL-1β production.
Succinate accumulation is an inflammatory signal that induces IL-1β through HIF-1α. Conversely, negative regulation may involve limiting succinate accumulation or HIF-1α activity. Macrophage SUCLA2, a Krebs cycle enzyme, couples glutaminolysis to AMPK signaling and manipulates obesity, suggesting that mitochondrial metabolic enzymes can influence IL-1β production. These findings highlight the role of mitochondrial metabolites as checkpoints in IL-1β regulation.
Immune Checkpoint-Mediated Suppression (Tim-3)
In simple terms: Certain immune receptors act as brakes on macrophage activation.
Increased Tim-3 (HAVCR2) expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice. Tim-3 is an immune checkpoint that can negatively regulate macrophage-driven inflammation, including IL-1β production. This demonstrates that cell-surface receptors can deliver inhibitory signals to reduce IL-1β output.
Transcriptional and Post-Transcriptional Control
In simple terms: The cell can reduce the amount of IL-1β mRNA or protein made.
Negative regulation of IL-1β production can also occur at the level of gene transcription or mRNA stability, although specific mechanisms are less well defined in the provided literature. The overall process ensures that IL-1β is produced only when needed and is rapidly shut down to prevent collateral damage.
Key Genes Involved in GO:0032691 negative regulation of interleukin-1 beta production
The following genes and proteins have been experimentally linked to the negative regulation of IL-1β production or to related inflammatory pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTPN6 | Inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation | Negative regulator of IL-1β production; target for inflammation studies |
| HAVCR2 (Tim-3) | Immune checkpoint that suppresses macrophage activation | Alleviates liver injury in NASH; potential therapeutic target |
| HCAR1 (GPR81) | Lactate receptor that suppresses innate immunity | Reduces inflammasome-mediated inflammation in liver and pancreas |
| SUCLA2 | Mitochondrial enzyme coupling glutaminolysis to AMPK | Manipulates obesity; links metabolism to IL-1β regulation |
| HIF1A | Transcription factor induced by succinate | Mediates succinate-driven IL-1β induction; target for negative regulation |
| IL1B | Pro-inflammatory cytokine | The production of which is negatively regulated by GO:0032691 |
| CASP8 | Initiator caspase involved in inflammasome signaling | Inhibited by Ptpn6 to reduce IL-1β |
| RIPK3 | Kinase in necroptosis and inflammasome activation | Inhibited by Ptpn6 to limit inflammation |
| MLKL | Executioner of necroptosis | Inhibited by Ptpn6 to reduce IL-1β |
| AMPK | Energy sensor kinase | Mediates SUCLA2 effects on obesity and inflammation |
| GPR81 | G-protein-coupled receptor for lactate | Mediates lactate-induced suppression of innate immunity |
| Tim-3 | Immune checkpoint receptor | Negatively regulates macrophage activation in NASH |
| IL-1β | Cytokine product | The ultimate target of negative regulation |
| Caspase-1 | Inflammasome caspase | Cleaves pro-IL-1β; indirectly regulated by negative pathways |
| NLRP3 | Inflammasome sensor | Inflammasome activation is suppressed by lactate-GPR81 signaling |
| NF-κB | Transcription factor for IL1B | Can be modulated by negative regulatory pathways |
| TNF | Pro-inflammatory cytokine | Linked to obesity and osteoarthritis; interacts with IL-1β networks |
| IL-6 | Pro-inflammatory cytokine | Co-regulated with IL-1β in inflammatory diseases |
How Is negative regulation of interleukin-1 beta production Regulated?
Negative regulation of IL-1β production is controlled by multiple intersecting pathways. The lactate-GPR81 axis suppresses inflammasome-mediated inflammation, while Ptpn6 inhibits caspase-8 and Ripk3/Mlkl signaling. Mitochondrial metabolites such as succinate can promote IL-1β via HIF-1α, but negative regulation may involve limiting succinate or HIF-1α activity. SUCLA2 and AMPK link glutaminolysis to obesity and inflammation. Tim-3 provides an immune checkpoint that dampens macrophage activation. These regulatory layers ensure that IL-1β production is tightly controlled.
negative regulation of interleukin-1 beta production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTPN6 | Inflammatory tissue injury | Knockout mice, macrophage cell lines |
| HAVCR2 (Tim-3) | NASH, liver injury | MCD-induced NASH mice, Tim-3 overexpression |
| HCAR1 (GPR81) | Liver and pancreatic injury | GPR81 knockout mice, lactate treatment |
| SUCLA2 | Obesity | Macrophage-specific SUCLA2 knockout mice |
| HIF1A | Inflammation | HIF-1α knockout or knockdown in macrophages |
Osteoarthritis and Obesity
Pro-inflammatory cytokines, including IL-1β, link obesity to osteoarthritis. Negative regulation of IL-1β production is therefore critical in preventing cartilage degradation and joint inflammation. Macrophage SUCLA2 and AMPK signaling also manipulate obesity, suggesting that metabolic control of IL-1β contributes to osteoarthritis pathogenesis.
Acne and Skin Inflammation
Diet-derived metabolites and inflammation contribute to acne pathogenesis, with IL-1β playing a role in comedogenesis. Negative regulation of IL-1β production may be relevant to therapeutic strategies for acne.
Nonalcoholic Steatohepatitis (NASH) and Liver Injury
Tim-3 upregulation alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice. Lactate reduces liver and pancreatic injury via GPR81-mediated suppression of innate immunity. These findings highlight the importance of negative regulation of IL-1β in liver disease.
Inflammatory Tissue Injury
Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation, protecting against tissue damage. Succinate-driven IL-1β through HIF-1α is an inflammatory signal that can exacerbate injury. Thus, negative regulation of IL-1β is a key protective mechanism.
From negative regulation of interleukin-1 beta production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of Ptpn6 increase IL-1β production? | PTPN6 knockout macrophages or mice |
| Does Tim-3 overexpression reduce IL-1β in NASH? | Tim-3 knock-in or overexpression in MCD mice |
| Does GPR81 activation suppress inflammasome? | GPR81 point mutation or knockout |
| Does SUCLA2 deficiency alter obesity via IL-1β? | Macrophage-specific SUCLA2 knockout |
| Does HIF-1α mediate succinate-induced IL-1β? | HIF1A knockout or point mutation |
| Can CRISPR activation of negative regulators reduce IL-1β? | CRISPRa overexpression library screening |
How to Study the negative regulation of interleukin-1 beta production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | IL-1β protein concentration | Quantify cytokine production in supernatants |
| Western blot | Pro-IL-1β and cleaved IL-1β | Assess inflammasome processing |
| RNA-seq | Transcriptome changes | Identify negative regulators of IL1B expression |
| Seahorse assay | Glycolysis and oxidative phosphorylation | Link metabolism to IL-1β regulation |
| Mass spectrometry | Metabolite levels (succinate, lactate) | Measure metabolic signals |
| CRISPR screen | Gene knockouts affecting IL-1β | Discover novel negative regulators |
| Flow cytometry | Intracellular IL-1β | Single-cell analysis of cytokine production |
| Co-immunoprecipitation | Protein-protein interactions | Study Ptpn6 interactions |
Cytokine Production Assays
ELISA and cytokine bead arrays measure IL-1β levels in culture supernatants or serum, providing direct readouts of negative regulation.
Inflammasome Activation Assays
Western blotting for cleaved caspase-1 and IL-1β, plus ASC speck formation, assess inflammasome activity and its suppression.
Metabolic Flux Analysis
Seahorse and mass spectrometry measure succinate, lactate, and glutaminolysis, linking metabolism to IL-1β regulation.
CRISPR Functional Genomics
Genome-wide knockout or activation screens identify negative regulators of IL-1β production in macrophages.
How CRISPR Can Be Used to Study GO:0032691 negative regulation of interleukin-1 beta production
Knockout
CRISPR knockout of candidate negative regulators such as PTPN6, HAVCR2, or HCAR1 can confirm their role in suppressing IL-1β production. For example, Ptpn6 knockout macrophages show increased caspase-8- and Ripk3/Mlkl-dependent inflammation.
Point Mutation
Point mutations can dissect specific domains required for negative regulation. For instance, mutating the phosphatase domain of PTPN6 would test its catalytic requirement in suppressing IL-1β.
Knock-in
Knock-in of tagged or reporter alleles (e.g., Tim-3-GFP) allows tracking of negative regulator expression and localization in vivo during inflammation.
Overexpression
CRISPR activation or cDNA overexpression of negative regulators like Tim-3 or GPR81 can reduce IL-1β production and alleviate disease in models such as NASH or liver injury.
How EDITGENE Supports negative regulation of interleukin-1 beta production Research
Researchers studying negative regulation of interleukin-1 beta production-related genes often need to determine whether a candidate gene is causally involved in suppressing IL-1β, and which domains or pathways mediate this effect. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-1 beta production research.
Frequently Asked Questions About negative regulation of interleukin-1 beta production
What is GO:0032691?
GO:0032691 is the Gene Ontology term for negative regulation of interleukin-1 beta production, describing any process that stops, prevents, or reduces the frequency, rate, or extent of IL-1β production.
What genes are involved in negative regulation of interleukin-1 beta production?
Key genes include PTPN6, HAVCR2 (Tim-3), HCAR1 (GPR81), SUCLA2, and HIF1A, as shown in studies of inflammation and metabolism.
How is IL-1β production negatively regulated?
It can be negatively regulated by inhibition of inflammasome signaling (e.g., Ptpn6), metabolic suppression (lactate-GPR81), immune checkpoints (Tim-3), and mitochondrial metabolic control (SUCLA2, HIF-1α).
What diseases are linked to dysregulated IL-1β production?
Osteoarthritis, acne, NASH, obesity, and inflammatory tissue injury are associated with altered IL-1β regulation.
What is the role of Ptpn6 in IL-1β regulation?
Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation, thereby reducing IL-1β production.
How does lactate suppress IL-1β?
Lactate acts through GPR81 to suppress innate immunity and inflammasome-mediated inflammation in liver and pancreatic injury.
What is the connection between SUCLA2 and IL-1β?
Macrophage SUCLA2 couples glutaminolysis to AMPK signaling and manipulates obesity, linking mitochondrial metabolism to IL-1β regulation.
Can Tim-3 reduce IL-1β in liver disease?
Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice.
How can CRISPR be used to study negative regulation of IL-1β?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to test the causal role of candidate genes in suppressing IL-1β production.
What methods measure IL-1β production?
ELISA, Western blot, RNA-seq, flow cytometry, and CRISPR screens are commonly used to measure IL-1β production and its regulation.
Conclusion
GO:0032691 negative regulation of interleukin-1 beta production encompasses diverse molecular mechanisms that keep the potent cytokine IL-1β in check. From phosphatase-mediated inhibition of inflammasome signaling to metabolic and immune checkpoint control, these pathways are essential for preventing inflammatory and metabolic diseases. CRISPR-based models and functional genomics offer powerful tools to dissect these mechanisms and identify new therapeutic targets.
References
- 1. Tannahill GM et al.. 2013. Succinate is an inflammatory signal that induces IL-1β through HIF-1α.. Nature 496(7444):238-42 PMID: 23535595
- 2. Wang T et al.. 2018. Pro-inflammatory cytokines: The link between obesity and osteoarthritis.. Cytokine Growth Factor Rev 44:38-50 PMID: 30340925
- 3. Melnik BC. 2015. Linking diet to acne metabolomics, inflammation, and comedogenesis: an update.. Clin Cosmet Investig Dermatol 8:371-88 PMID: 26203267
- 4. Peng C et al.. 2025. Macrophage SUCLA2 coupled glutaminolysis manipulates obesity through AMPK.. Nat Commun 16(1):1738 PMID: 39966410
- 5. Du X et al.. 2019. Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice.. Cell Mol Immunol 16(11):878-886 PMID: 29735977
- 6. Speir M et al.. 2020. Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation.. Nat Immunol 21(1):54-64 PMID: 31819256
- 7. Newton RC. 1990. The production of human interleukin-1 beta by blood monocytes.. Prog Clin Biol Res 349:217-28 PMID: 2204930
- 8. Hoque R et al.. 2014. Lactate reduces liver and pancreatic injury in Toll-like receptor- and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity.. Gastroenterology 146(7):1763-74 PMID: 24657625
